Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility

Tarek Kashour, Rabih Halwani, Yaseen M. Arabi, M. Rizwan Sohail, John C. O’Horo, Andrew D. Badley, Imad M. Tleyjeh

Research output: Contribution to journalReview articlepeer-review

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the coronavirus disease 2019 (COVID-19) has infected millions of individuals and has claimed hundreds of thousands of human lives worldwide. Patients with underlying cardiovascular conditions are at high risk for SARS-CoV-2 infection, and COVID-19 patients have high incidence of cardiovascular complications such as acute cardiac injury, arrhythmias, heart failure, and thromboembolism. The disease has no approved proven effective therapy and hence repurposing of existing approved drugs has been considered as the fastest treatment approach. Statins have been shown to exhibit lipid lowering dependent and independent cardiovascular protective effects as well as favorable effects in various other pathophysiological states. These beneficial properties of statins are a result of their multiple pleotropic effects that include, anti-inflammatory, immunomodulatory, antithrombotic and antimicrobial properties. In this review, we provide a comprehensive description of the mechanisms of the pleotropic effects of statins, the relevant pre-clinical and clinical data pertinent to their role in infections and acute lung injury, the possible cardiovascular benefits of statins in COVID-19, and the implications of the therapeutic potential of statins in COVID-19 disease. We conclude with the rationale for conducting randomized controlled trials of statins in COVID-19 disease.

Original languageEnglish (US)
Pages (from-to)37-50
Number of pages14
JournalImmunopharmacology and Immunotoxicology
Volume43
Issue number1
DOIs
StatePublished - 2021

Keywords

  • ARDS
  • COVID-19
  • SARS-CoV-2
  • Statins
  • acute lung injury
  • anti-inflammatory
  • antiviral
  • immunomodulatory

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility'. Together they form a unique fingerprint.

Cite this